Enabling Equitable Access to COVID-19 Vaccine in Under-Resourced Communities
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 1,722
- 试验地点
- 2
- 主要终点
- Dose 1 COVID-19 Vaccine
研究概览
简要总结
This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations and address vaccine hesitancy to improve access by using a proactive organized population-based outreach leveraging health information technology with tailored navigation support to address mistrust and social barriers.
详细描述
This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations through a proactive organized population-based outreach approach. It will leverage health information technology with tailored navigation support to address mistrust and social barriers. Study key objectives are to:
-
conduct a survey of patients to assess and track barriers, intent, and sources of information on COVID vaccine over time.
-
Determine whether a primary care physician (PCP) endorsement with or without interactive digital communication plus navigation is more effective in promoting uptake of COVID-19 vaccine than general messages from the clinic. Patients will be randomized to one of three arms:
-
Arm 1: Message about vaccine availability delivered by SMS advising patients to make an appointment.
-
Arm 2: Same as Arm 1 but delivered as a personalized message text from the PCP.
-
Arm 3: Same as Arm 2 plus a interactive 2-way SMS options.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18 years and older, receiving care at Adelante Healthcare and not vaccinated or already scheduled for vaccination through the health center's appointment system
排除标准
- •Patient younger than 18 or who have been previously or are selected for vaccination during or prior to the week of study enrollment
结局指标
主要结局
Dose 1 COVID-19 Vaccine
时间窗: 30 days
Primary outcome will be the receipt of the first dose of any of the COVID-19 vaccines with FDA emergency use authorization
次要结局
- Dose 2 COVID-19 Vaccine(60 days)
研究者
Chyke A. Doubeni
Principal Investigator
Mayo Clinic